Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

NCT05296603 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

83

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: IBI-322 Plus Lenvatinib

Sponsor

Hunan Province Tumor Hospital